Literature DB >> 26258003

Hypersomnia in Mood Disorders: a Rapidly Changing Landscape.

David T Plante1.   

Abstract

Hypersomnia is commonly comorbid with depressive illness and is associated with treatment resistance, symptomatic relapse, and functional impairment. This review highlights recent changes in nosological classifications of hypersomnia. In addition, emergent findings regarding the neurobiologic underpinnings, assessment, and treatment of hypersomnia in mood disorders are reviewed, as well as the effects of hypersomnolence on illness course. Future strategies for research are proposed that may elucidate the causes of hypersomnia in mood disorders and lead to the development of improved diagnostic and therapeutic strategies.

Entities:  

Keywords:  Arousal; Depression; Hypersomnia; Mood disorders; Nosology; Sleepiness

Year:  2015        PMID： 26258003      PMCID： PMC4526256          DOI： 10.1007/s40675-015-0017-9

Source DB:  PubMed          Journal:  Curr Sleep Med Rep        ISSN： 2198-6401


  71 in total

Review 1.  The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission.

Authors:  T de Boer
Journal:  Int Clin Psychopharmacol       Date:  1995-12       Impact factor: 1.659

Review 2.  Hypothalamic regulation of sleep and circadian rhythms.

Authors:  Clifford B Saper; Thomas E Scammell; Jun Lu
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

3.  Teen sleep and suicidality: results from the youth risk behavior surveys of 2007 and 2009.

Authors:  Caris T Fitzgerald; Erick Messias; Daniel J Buysse
Journal:  J Clin Sleep Med       Date:  2011-08-15       Impact factor: 4.062

4.  Trajectories of individual symptoms in remitters versus non-remitters with depression.

Authors:  Hitoshi Sakurai; Hiroyuki Uchida; Takayuki Abe; Shinichiro Nakajima; Takefumi Suzuki; Bruce G Pollock; Yuji Sato; Masaru Mimura
Journal:  J Affect Disord       Date:  2013-07-22       Impact factor: 4.839

5.  Challenging the validity of the association between oversleeping and overeating in atypical depression.

Authors:  Maurice M Ohayon; Laura Weiss Roberts
Journal:  J Psychosom Res       Date:  2014-10-02       Impact factor: 3.006

Review 6.  Stimulants for treating bipolar disorder: pro and con.

Authors:  Heinz Grunze
Journal:  Harv Rev Psychiatry       Date:  2014 Nov-Dec       Impact factor: 3.732

7.  Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression.

Authors:  Eleni Aklillu; Sara Karlsson; Olof O Zachrisson; Vural Ozdemir; Hans Agren
Journal:  Pharmacogenet Genomics       Date:  2009-04       Impact factor: 2.089

Review 8.  Armodafinil.

Authors:  Karly P Garnock-Jones; Sohita Dhillon; Lesley J Scott
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

9.  Sleep disturbance preceding completed suicide in adolescents.

Authors:  Tina R Goldstein; Jeffrey A Bridge; David A Brent
Journal:  J Consult Clin Psychol       Date:  2008-02

10.  Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.

Authors:  Charles DeBattista; Karl Doghramji; Matthew A Menza; Murray H Rosenthal; Ronald R Fieve
Journal:  J Clin Psychiatry       Date:  2003-09       Impact factor: 4.384
View more
  8 in total

1.  Reduced resting-state thalamostriatal functional connectivity is associated with excessive daytime sleepiness in persons with and without depressive disorders.

Authors:  David T Plante; Rasmus M Birn; Erin C Walsh; Roxanne M Hoks; M Daniela Cornejo; Heather C Abercrombie
Journal:  J Affect Disord       Date:  2017-11-14       Impact factor: 4.839

2.  Establishing the objective sleep phenotype in hypersomnolence disorder with and without comorbid major depression.

Authors:  David T Plante; Jesse D Cook; Leonardo S Barbosa; Michael R Goldstein; Michael L Prairie; Richard F Smith; Brady A Riedner
Journal:  Sleep       Date:  2019-06-11       Impact factor: 5.849

3.  Development and validation of the Hypersomnia Severity Index (HSI): A measure to assess hypersomnia severity and impairment in psychiatric disorders.

Authors:  Katherine A Kaplan; David T Plante; Jesse D Cook; Allison G Harvey
Journal:  Psychiatry Res       Date:  2019-08-31       Impact factor: 3.222

4.  Mood disorders are highly prevalent in patients investigated with a multiple sleep latency test.

Authors:  Eve J Denton; Maree Barnes; Tom Churchward; Melinda Jackson; Allison Collins; Matthew T Naughton; Eli Dabscheck
Journal:  Sleep Breath       Date:  2017-10-09       Impact factor: 2.816

5.  Subjective and Objective Measures of Hypersomnolence Demonstrate Divergent Associations with Depression among Participants in the Wisconsin Sleep Cohort Study.

Authors:  David T Plante; Laurel A Finn; Erika W Hagen; Emmanuel Mignot; Paul E Peppard
Journal:  J Clin Sleep Med       Date:  2016-04-15       Impact factor: 4.062

6.  Self-reported symptoms and objective measures in idiopathic hypersomnia and hypersomnia associated with psychiatric disorders: a prospective cross-sectional study.

Authors:  Jitka Bušková; Tomáš Novák; Eva Miletínová; Radana Králová; Jana Košt Álová; Monika Kliková; Karolina Veldová
Journal:  J Clin Sleep Med       Date:  2022-03-01       Impact factor: 4.062

7.  Comparison of Genetic Liability for Sleep Traits Among Individuals With Bipolar Disorder I or II and Control Participants.

Authors:  Katie J S Lewis; Alexander Richards; Robert Karlsson; Ganna Leonenko; Samuel E Jones; Hannah J Jones; Katherine Gordon-Smith; Liz Forty; Valentina Escott-Price; Michael J Owen; Michael N Weedon; Lisa Jones; Nick Craddock; Ian Jones; Mikael Landén; Michael C O'Donovan; Arianna Di Florio
Journal:  JAMA Psychiatry       Date:  2020-03-01       Impact factor: 21.596

Review 8.  Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials.

Authors:  Alexander J Scott; Thomas L Webb; Marrissa Martyn-St James; Georgina Rowse; Scott Weich
Journal:  Sleep Med Rev       Date:  2021-09-23       Impact factor: 11.609
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.